Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04966325 · ClinicalTrials.gov registry record · Early Phase 1
Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
A Early Phase 1 study, sponsored by LG Chem.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 37
- Enrollment target
NCT04966325: Completed Early Phase 1 study, sponsored by LG Chem.
NCT04966325 is a Early Phase 1 study that has completed, run by LG Chem. The registered enrollment target is 37 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04966325, a Early Phase 1 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is a Phase 1, single-center, randomized, partially double-blind, placebo- and positive controlled, 4-way crossover study to evaluate the effect of a therapeutic and a supratherapeutic dose of LC350189 on the QTcF in healthy male and female subjects.
Primary Outcome
QTcF will be analyzed using concentration-QT (cQT) modeling
Interventions
- DRUG Placebo
- DRUG Moxifloxacin 400mg
- DRUG LC350189 200mg
- DRUG LC350189 600mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2021-12-07 |
| Phase | Early Phase 1 |
What the finished NCT04966325 record still lists
NCT04966325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04966325 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04966325 about?
NCT04966325 is a clinical study titled "Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects". This is a Phase 1, single-center, randomized, partially double-blind, placebo- and positive controlled, 4-way crossover study to evaluate the effect of a therapeutic and a supratherapeutic dose of LC350189 on the QTcF in healthy male and female subjects.
What is the current status of trial NCT04966325?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 37 participants. The study started on 2021-09-23. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT04966325?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin 400mg (DRUG), LC350189 200mg (DRUG), LC350189 600mg (DRUG).
Who is sponsoring clinical trial NCT04966325?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04966325's enrollment target sits among peer trials
37 703rd of 2000 higher than 1,290 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI